Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,448.36
(
-2.19%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.57
(
5.86%
)
Bitcoin
65,898.01
(
-4.19%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: caravon post# 198683

Wednesday, 12/30/2015 8:30:05 PM

Wednesday, December 30, 2015 8:30:05 PM

Post# of 257295

…ABBV decided stay away from other HCV GT groups.

Actually, the phase-3 program for ABT-493/ABT-530 is testing all genotypes—see the next post—so I presume you meant to say that the head-to-head trial against Sovaldi/Daklinza is only for GT3 patients. That’s true but unrevealing insofar as GT3 is the only genotype where the Sovaldi/Daklinza combination is likely to be used.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today